Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Royalty Pharma (NASDAQ:RPRX) has announced the acquisition of a royalty interest in Amgen's Imdelltra from BeOne Medicines for $885 million upfront, with an additional $65 million option available to BeOne within 12 months. The deal involves approximately 7% royalty on worldwide net sales of Imdelltra, extending through 2038-2041.
Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), received FDA accelerated approval in May 2024 for treating extensive-stage small cell lung cancer. The drug achieved $215 million in sales during H1 2025 and is projected to reach $2.8 billion by 2035. The agreement includes royalty sharing with BeOne on annual net sales above $1.5 billion, while BeOne retains China commercial rights.
BeOne Medicines (Nasdaq: ONC) has entered into a significant royalty purchase agreement with Royalty Pharma for up to $950 million for IMDELLTRA® worldwide sales rights (excluding China). The deal includes an $885 million upfront payment and a potential additional $65 million within 12 months.
IMDELLTRA® is a groundbreaking DLL-3 targeting bispecific T-cell engager approved for treating extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after platinum-based chemotherapy. BeOne will retain a portion of royalties on annual sales above $1.5 billion and maintain rights to other assets under its Amgen collaboration, including xaluritamig.
Royalty Pharma (NASDAQ:RPRX) announced that Henry Fernandez has stepped down from his position as Lead Independent Director on the company's Board of Directors, effective August 13, 2025. Fernandez joined the board in July 2020 and was appointed Lead Independent Director in March 2021.
During his tenure, Fernandez contributed to several company milestones, including the completion of internalization. CEO Pablo Legorreta praised Fernandez's leadership and business expertise, particularly valuable during Royalty Pharma's early years as a public company. The company plans to appoint a new Lead Independent Director in the near future.
Royalty Pharma (NASDAQ:RPRX) reported strong Q2 2025 results with Portfolio Receipts growing 20% to $727 million and Royalty Receipts increasing 11% to $672 million. The company raised its full-year 2025 guidance, now expecting Portfolio Receipts between $3,050-$3,150 million, representing 9-12% growth.
Key Q2 highlights include the completion of external manager acquisition, a groundbreaking $2 billion funding agreement with Revolution Medicines, and $1 billion in share repurchases during H1 2025. The company maintained strong liquidity with $632 million in cash and $8.2 billion in total debt as of June 30, 2025.
Growth was primarily driven by strong performance from products including Voranigo, Trelegy, Evrysdi, and Tremfya, while positive clinical updates were reported across the portfolio, notably for Gilead's Trodelvy in breast cancer treatment.
Royalty Pharma (Nasdaq: RPRX) has announced its quarterly dividend payment for Q3 2025. The company will distribute a dividend of $0.22 per Class A ordinary share. The dividend is scheduled to be paid on September 10, 2025, to shareholders who are registered as of the record date on August 15, 2025.
Royalty Pharma (NASDAQ:RPRX) has appointed two new independent directors to its Board: Carole Ho, Chief Medical Officer at Denali Therapeutics, and Elizabeth Weatherman, Special Limited Partner at Warburg Pincus. The appointments increase independent board representation to over 90% and follow the company's acquisition of its external manager.
Dr. Ho brings 20 years of biopharma experience, currently leading therapeutic development at Denali and previously serving as Vice President of Clinical Development at Genentech. Weatherman contributes 35 years of healthcare industry investment expertise from her tenure at Warburg Pincus, where she led the Healthcare Group and served on numerous corporate boards.
Royalty Pharma (NASDAQ:RPRX) has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day.
Investors can access the conference call details and live webcast through the company's website at their Investors page. A replay of both the call and webcast will remain available on Royalty Pharma's website for a minimum of 30 days following the event.
Royalty Pharma (RPRX) has completed the acquisition of its external manager, RP Management, LLC, with 99.9% shareholder approval. The internalization marks a significant shift from the company's previous external management model that had been in place since 1996. Under the former structure, Royalty Pharma paid quarterly fees of 6.5% of Portfolio Receipts and 0.25% of security investments value to RP Management.
The transaction integrates all RP Management employees into Royalty Pharma. Management team members (excluding CEO Pablo Legorreta) will receive about 50% of transaction equity, vesting through 2033. Legorreta's equity will vest over five years. The company will update its 2025 guidance to reflect this change in Q2 2025 results.
Royalty Pharma (NASDAQ: RPRX) has announced its participation in two major healthcare investor conferences in May 2025. The company will present at the BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET, and at the RBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET.
Both presentations will be available via webcast through Royalty Pharma's investor relations website and will remain archived for at least thirty days after the events.